Direction at a glance
Cell therapies attempt to provide persistent immune effectors that recognize conserved HIV targets, resist exhaustion or deliver antiviral molecules. Designs include expanded HIV-specific T cells, engineered receptors and NK-cell approaches.
What the evidence establishes
- Small phase 1 studies can establish feasibility and short-term safety, not cure efficacy.
- A 2025 open-label study evaluated autologous HIV-specific T cells in six adults.
- A 2026 first-in-human study reported safety and biologic activity for a bispecific T-cell receptor targeting HIV Gag.
Next decisive research questions
Limits and responsible interpretation
What this direction does not yet prove
Current studies are small and early. Manufacturing, tissue access, antigen escape and safety monitoring limit near-term scale.
Development pathway
| Decision | Required evidence |
|---|---|
| Biological activity | Target engagement and an outcome that cannot be explained by assay noise or selection. |
| Clinical value | Meaningful benefit, adequate follow-up, safety, comparison with current standard care and transparent uncertainty. |
| Generalizability | Diverse populations, subtypes, geographies, ages and clinically relevant comorbidities. |
| Scalability | Manufacturing, delivery, monitoring, price, workforce and community acceptability. |
Principal sources and evidence gateways
Links checked 18 August 202601
Autologous HIV-specific T-cell therapy targeting conserved epitopesNature Communications · Primary research · Access checked 18 Aug 2026
↗02First-in-human trial of a bispecific T-cell receptor targeting HIV GagNature Communications · Primary research · Access checked 18 Aug 2026
↗03ClinicalTrials.gov HIV study registryU.S. National Library of Medicine · Registry · Access checked 18 Aug 2026
↗